The FDA has accepted Sanofi and Regeneron’s application to expand Dupixent’s use, with a decision expected by April 2025.

Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activityMore ...

Regeneron and Sanofi's Dupixent sBLA for treating chronic spontaneous urticaria in patients 12+ gets FDA review, with a ...

Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activityMore than 300,000 people in the U.S.

We tend to think of COVID-19 as a respiratory illness. But, like many viruses, COVID can also affect your skin and cause ...

In May 2024, Novartis announced new data that confirm the long-term efficacy and safety of remibrutinib, a highly selective ...

This article will discuss the key differences between hives and eczema in their symptoms, causes, diagnosis, and treatment. Eczema, also called atopic dermatitis, is a chronic skin condition ...

Dementia treatment is more than just medication. It can include lifestyle changes, multimodal therapy, and environmental management, as well. Your dementia treatment plan will depend on underlying ...

Itchy, red bumps with fluid-filled blisters—these are the signs of papular urticaria, an allergic reaction to a bug bite. But ...

In November 2021, however, she came up against a case nearly impossible to solve. It all started when Elisha woke up with an ...

Medically reviewed by Jurairat J. Molina, MD Acute urticaria (hives) is a common skin condition that affects up to 20% of people at some point in their lives. It can transition into chronic urticaria ...